Introduction Patients with inflammatory bowel disease (IBD), particularly those receiving biologic therapies, are at increased risk of infections due to immunosuppression. Vaccinations play a vital role in reducing this risk, yet adherence to immunisation schedules remains suboptimal. This audit aimed to assess vaccination coverage among IBD patients on biologic therapies at Our Lady's Hospital, Navan, Ireland, and to identify areas for improvement. Aim and objectives The primary aim was to evaluate adherence to recommended immunisation schedules for IBD patients on biologics. Specific objectives were to assess uptake of vaccines including tetanus, diphtheria, and pertussis (Tdap), meningococcal, measles, mumps, and rubella (MMR), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), influenza, herpes zoster, human papillomavirus (HPV), hepatitis B virus (HBV), hepatitis A virus (HAV), and varicella-zoster virus (VZV), to identify gaps in coverage, and to propose interventions to improve adherence. Methods A retrospective review of 24 patients with IBD receiving regular biologic infusions at the hospital's day ward was conducted. Data collected included demographics, type of IBD, biologic therapy details, and vaccination status. The assessment was based on the European Crohn's and Colitis Organisation (ECCO)-aligned immunisation recommendations. Immunity to VZV was accepted based on documented infection history or serological confirmation. Results Among the 24 patients reviewed, 14 had ulcerative colitis and 10 had Crohn's disease. Sixteen were male and eight female. Twenty patients were on infliximab and four on vedolizumab. Vaccination coverage was generally low: Tdap (5/11, 45.5%), meningococcal (1/4, 25%), MMR (1/2, 50%), SARS-CoV-2 (0/4, 0%), influenza (1/10, 10%), HPV (1/3 eligible females, 33.3%), HBV (2/15, 13.3%), and HAV (0/4, 0%). All six patients with VZV data showed immunity. No documentation was available for herpes zoster vaccination. Conclusion The audit revealed significant gaps in adherence to vaccination guidelines among IBD patients receiving biologics. These findings highlight the need for systematic interventions to improve vaccine uptake, such as routine immunisation status reviews during clinic visits, improved documentation practices, patient education on vaccine safety and necessity, and stronger collaboration between gastroenterologists and primary care providers. Educational materials should be provided during clinic or infusion appointments to address vaccine hesitancy and misinformation. Implementing these changes could reduce the burden of vaccine-preventable diseases in this vulnerable population.
Khan et al. (2026) studied this question.